At a glance
ClinicalIndex Comparison RecordN/ACompleted· 43 enrolled
Drug / intervention
Left atrial appendage closure device WM FLX Prodevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Assess WATCHMAN FLX™ Pro Implants by Cardiac Computed Tomography, Magnetic Resonance Imaging and Transesophageal Echocardiography: WATCHMAN FLX Pro CT
In Brief
A clinical study evaluating Left atrial appendage closure device WM FLX Pro for Non-valvular Atrial Fibrillation (AF). Completed, enrolled 43 participants across 1 site.
Detailed Summary
The primary objective of this study is to measure device tissue coverage post-implantation of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device (WATCHMAN FLX Pro) using the serial advanced imaging modalities of cardiac computed tomography (CT) and transesophageal echocardiography (TEE) and assess its relationship, if any, to clinical events.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-valvular Atrial Fibrillation (AF)
CountriesDenmark
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartMar 2023
Primary CompletionOct 2024
Study CompletionJun 2025
TodayJul 2026
First PostedOct 5, 2022
Enrollment StartMar 24, 2023
Primary CompletionOct 14, 2024
Study CompletionJun 18, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 3.7 years ago
Interventions
Left atrial appendage closure device WM FLX Prodevice
Left atrial appendage closure